A Phase 3 Study of Extended-release Tacrolimus in Subjects With Pulmonary Arterial Hypertension and Functional Limitations
A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 300 participants.
Also called NCT07612657
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 300 participants
- Sponsor
- VIVUS LLC
- Registry
-
NCT07612657
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07612657. Randomized; triple masking; primary purpose treatment. Start 2026-05-29 (anticipated); primary completion 2028-05-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Phase 3 Study of Extended-release Tacrolimus in Subjects With Pulmonary Arterial Hypertension and Functional Limitations
- Acronym
- TRANSCEND
- Condition
- Pulmonary Arterial Hypertension
- Condition
- Pulmonary Arterial Hypertension (PAH)
- Condition
- Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)
- Condition
- Pulmonary Arterial Hypertension PAH
- Condition
- Pulmonary Arterial Hypertension WHO Group I
- Intervention (Drug)
- VI-0106
- Intervention (Drug)
- Placebo
- Lead sponsor
- VIVUS LLC
Record details
- Record id
cardio:ct-nct07612657- Content hash
a2a3f83f112c438c4d89789cd9e0678777f4824c95c03071909547f789264f55